Cart 0

MarketsandMarkets

Biosimilars Market- Global Forecast to 2021

$5,650.00

Report Published By: MarketsandMarkets
Publication Date : Jan-17
No. Of Pages: 154

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application (Oncology, Blood Disorders) - Global Forecast To 2021
The global biosimilars market is expected to reach USD 10.90 billion by 2021 from USD 3.39 billion in 2016, at a CAGR of 26.3%. The biosimilars market is broadly classified into product, manufacturing type, application, and region.
On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is estimated to account for the largest share of the biosimilars market, in 2016. Factors such as new product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are driving growth in this market.
On the basis of manufacturing type, the market is segmented into in-house manufacturing and contract manufacturing organizations. The contract manufacturing organizations segment is projected to witness the highest CAGR during the forecast period.
On the basis of application, the market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. In 2016, the oncology segment is expected to account for the largest share of the market.

Geographically, the biosimilars market is dominated by Europe, followed by Asia, North America, and the Rest of the World (RoW). Growth in the European market is attributed to the growing pressure to curtail healthcare costs, patent expiry of biologics & the arrival of new biosimilars, and the rising incidence of chronic disorders.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.
The key players in the biosimilars market include Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Biocon Ltd. (India), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion Inc. (South Korea), and Samsung Bioepis (South Korea).

Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the product portfolios of the top players in the biosimilars market. The report analyses the biosimilars market by product, manufacturing type, and application.
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the biosimilars market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biosimilars products across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKET COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 SECONDARY DATA 19
2.1.1 KEY DATA FROM SECONDARY SOURCES 19
2.2 PRIMARY DATA 20
2.2.1 KEY DATA FROM PRIMARY SOURCES 21
2.3 MARKET SIZE ESTIMATION 22
2.3.1 BOTTOM-UP APPROACH 22
2.3.2 TOP-DOWN APPROACH 23
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 24
2.5 ASSUMPTIONS FOR THE STUDY 25
3 EXECUTIVE SUMMARY 26
3.1 INTRODUCTION 26
3.2 CONCLUSION 29
4 PREMIUM INSIGHTS 30
4.1 BIOSIMILARS: MARKET OVERVIEW 30
4.2 GEOGRAPHIC ANALYSIS: BIOSIMILARS MARKET, BY PRODUCT 31
4.3 BIOSIMILARS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 32
5 MARKET OVERVIEW 33
5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Rising incidences of diseases 35
5.2.1.2 Increasing demand for biosimilar drugs due to their cost-effectiveness 36
5.2.1.3 Growing pressure to curtail healthcare expenditure 36
5.2.1.4 Rising geriatric population 37
5.2.1.5 Strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars 38
5.2.1.6 Increasing government support and initiatives to develop and promote biosimilars 39
5.2.2 RESTRAINTS 39
5.2.2.1 Complexities in manufacturing and high costs 39
5.2.2.2 Innovative strategies by biologic drug manufacturers 40
5.2.3 OPPORTUNITIES 40
5.2.3.1 Emerging markets 40
5.2.3.2 New indications and patent expiry of biologic products 40
5.2.4 CHALLENGE 42
5.2.4.1 Stringent regulatory requirements to adversely affect investments in biosimilars 42
5.3 KEY PIPELINE PRODUCTS 42
5.4 REGULATORY OUTLOOK 44
5.4.1 NORTH AMERICA 44
5.4.1.1 U.S. 44
5.4.1.2 Canada 44
5.4.2 EUROPE 44
5.4.3 ASIA 45
5.4.3.1 China 45
5.4.3.2 India 46
5.4.3.3 Japan 46
5.4.3.4 South Korea 46
5.4.4 REST OF THE WORLD 46
5.4.4.1 Brazil 46
5.4.4.2 Mexico 46
5.4.4.3 Argentina 47
5.4.4.4 Saudi Arabia 47
5.5 BIOSIMILARS SERVICES INDUSTRY INSIGHTS 47
5.5.1 INTRODUCTION 47
5.5.2 CONTRACT MANUFACTURING ORGANIZATIONS 48
5.5.3 CONTRACT RESEARCH ORGANIZATIONS 48
5.5.4 OTHER SERVICES (NONCLINICAL & BIOINFORMATICS) 49
6 BIOSIMILARS MARKET, BY TYPE OF PRODUCT 50
6.1 INTRODUCTION 51
6.2 RECOMBINANT NON-GLYCOSYLATED PROTEINS 52
6.2.1 INSULIN 54
6.2.2 RECOMBINANT HUMAN GROWTH HORMONE (RHGH) 55
6.2.3 GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM) 56
6.2.4 INTERFERONS 58
?
6.3 RECOMBINANT GLYCOSYLATED PROTEINS 59
6.3.1 ERYTHROPOIETIN (EPO) 61
6.3.2 MONOCLONAL ANTIBODIES (MABS) 62
6.3.3 FOLLITROPIN 63
6.4 RECOMBINANT PEPTIDES 64
6.4.1 GLUCAGON 66
6.4.2 CALCITONIN 66
7 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING 68
7.1 INTRODUCTION 69
7.2 IN-HOUSE MANUFACTURING 70
7.3 CONTRACT MANUFACTURING ORGANIZATIONS 71
8 BIOSIMILARS MARKET, BY APPLICATION 72
8.1 INTRODUCTION 73
8.2 ONCOLOGY 74
8.3 CHRONIC AND AUTOIMMUNE DISEASES 76
8.4 BLOOD DISORDERS 77
8.5 GROWTH HORMONE DEFICIENCY 78
8.6 INFECTIOUS DISEASES 79
8.7 OTHER APPLICATIONS 80
9 BIOSIMILARS MARKET, BY REGION 81
9.1 INTRODUCTION 82
9.2 NORTH AMERICA 83
9.2.1 U.S. 88
9.2.2 CANADA 89
9.3 EUROPE 90
9.3.1 GERMANY 95
9.3.2 FRANCE 95
9.3.3 U.K. 96
9.3.4 ITALY 97
9.3.5 SPAIN 97
9.3.6 REST OF EUROPE 98
9.4 ASIA 99
9.4.1 CHINA 104
9.4.2 INDIA 105
9.4.3 JAPAN 106
9.4.4 SOUTH KOREA 107
9.4.5 REST OF ASIA (ROA) 108
9.5 REST OF THE WORLD (ROW) 109
10 COMPETITIVE LANDSCAPE 113
10.1 OVERVIEW 113
10.2 MARKET SHARE ANALYSIS 114
10.3 COMPETITIVE SITUATION AND TRENDS 115
10.3.1 REGULATORY APPROVALS 116
10.3.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 116
10.3.3 PRODUCT LAUNCHES 117
10.3.4 ACQUISITIONS 118
10.3.5 EXPANSIONS 118
10.3.6 OTHER DEVELOPMENTS 119
11 COMPANY PROFILES 120
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 INTRODUCTION 120
11.2 PFIZER INC. 121
11.3 SANDOZ INTERNATIONAL GMBH (A DIVISION OF NOVARTIS INTERNATIONAL AG) 123
11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 126
11.5 F. HOFFMANN-LA ROCHE LTD. 128
11.6 AMGEN INC. 130
11.7 BIOCON LTD. 132
11.8 DR. REDDY'S LABORATORIES 134
11.9 CELLTRION INC. 136
11.10 MYLAN INC. 138
11.11 SAMSUNG BIOEPIS 140

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
12 APPENDIX 142
12.1 INSIGHTS OF INDUSTRY EXPERTS 142
12.2 DISCUSSION GUIDE 143
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 147
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 149
12.5 AVAILABLE CUSTOMIZATIONS 150
12.6 RELATED REPORTS 151
12.7 AUTHOR DETAILS 152

* indicates required information

* indicates required information


Share this Product


More from this collection